Details:
This new published patent application relates, inter alia, to a new salt of mesdopetam that is intended to be included in the final pharmaceutical product.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
The acceptance of the IND will allow IRLAB to include US patients in the upcoming clinical trial in Parkinson’s disease in accordance with the study protocol. The planned Phase IIb/III study for mesdopetam will thus include hospitals and enrol patients in the US and Europe.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
When mesdopetam was given in addition to standard Parkinson medication, patients experienced considerably longer periods of good daily motor function without aggravated involuntary movements.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020